title: [Effect of nitric oxide donor and alpha1-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro].
abstract: OBJECTIVE
  To study the effect of nitric oxide donor and alpha(1)-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro.
  
  
  METHODS
  Primary cultured prostatic stromal cells were treated by nitric oxide donor SNP and Terazosin, and the antiproliferative index and apoptosis index were determined by MTT assay and TUNEL respectively.
  
  
  RESULTS
  There was a significant dose-effect relationship between SNP and the antiproliferative effects, while Terazosin showed no antiproliferative effects and the combination of SNP and Terazosin showed no strengthen effects. Terazosin significantly induced apoptosis, but SNP showed no effect on induction of apoptosis, while there were much more effects of inducing apoptosis in the combination of Terazosin and SNP than the Terazosin alone.
  
  
  CONCLUSIONS
  Terazosin induces apoptosis in cultured BPH stromal SMCs with little effect on the cell proliferation. SNP inhibits the proliferation of the cells without affecting apoptosis. The apoptosis induction effect is enhanced when Terazosin is combined with SNP, but they do not have an additive antiproliferative effect.
authors.affiliation: Department of Urology, First Affiliated Hospital, Zhongshan (Sun Yat-sen) University, Guangzhou 510080, China.
authors.forename: Chun-hua
authors.initials: CH
authors.lastname: Deng
authors.forename: Hui-rong
authors.initials: HR
authors.lastname: Chen
authors.forename: Shao-peng
authors.initials: SP
authors.lastname: Qiu
authors.forename: Jian-zhong
authors.initials: JZ
authors.lastname: Liu
authors.forename: Ke-li
authors.initials: KL
authors.lastname: Zheng
authors.forename: Hua
authors.initials: H
authors.lastname: Mei
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D020287:In Situ Nick-End Labeling; D008297:Male; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000473:pathology; D017154:Stromal Cells / Q000187:drug effects / Q000473:pathology
chemical_list: D000317:Adrenergic alpha-Antagonists; D020030:Nitric Oxide Donors; C041226:Terazosin; D011224:Prazosin